Hypothesis

A distinct subpopulation of senescent cells—characterized by low mitochondrial ROS, high NAD⁺, and a PDGF‑AA‑rich secretome—acts as a transient niche that activates resident stem cells during acute injury. In contrast, senescent cells that accumulate with age exhibit elevated mtROS, cytosolic DNA release, and a proinflammatory SASP that converts the niche into a fibrotic, inhibitory environment. Broad senolytics eliminate both subsets, inadvertently wiping out the regenerative niche while attempting to clear the pathogenic load. Restoring the balance by sparing the low‑mtROS/PDGF‑AA+ senescent cells should preserve tissue repair capacity while still alleviating age‑related pathology.

Mechanistic Basis

Transient senescent cells arise during wound healing and express p21 at moderate levels, secrete PDGF‑AA, and package it into exosomes that stimulate stromal stem‑cell proliferation (Senescent cells play an essential role in wound healing). Their mitochondria remain functional, NAD⁺ levels are high, and they avoid cGAS‑STING activation, limiting SASP output. With age, declining immune surveillance allows damaged cells to persist (age‑related accumulation of senescent cells is driven by a decline in immune surveillance). Persistent senescent cells accumulate mtROS, release oxidized mitochondrial DNA, and trigger chronic cGAS‑STING signaling, amplifying IL‑6, IL‑8, and MMP production that destabilizes the extracellular matrix and suppresses stem‑cell activity (The threshold hypothesis proposes that senescent cell burden becomes pathological only when it exceeds tissue sustainability).

Salamander limb regeneration shows that macrophage‑dependent clearance rapidly removes senescent cells after they have delivered their regenerative signal, preventing accumulation (During salamander limb regeneration, cellular senescence is induced reproducibly, but efficient macrophage‑dependent immunosurveillance rapidly clears senescent cells). In mammals, the same clearance mechanism falters, allowing the pathogenic subset to dominate.

Testable Predictions

1. Marker distinction: In young mouse skin after full‑thickness wound, p21⁺/PDGF‑AA⁺/mtROSlow senescent cells peak at 2‑days post‑injury and decline by day 5, whereas p21⁺/SASP‑high/mtROS^high cells are negligible. In aged mice, the mtROS^high/SASP‑high population persists beyond day 10.
2. Functional assay: Isolating the p21⁺/PDGF‑AA⁺/mtROS^low fraction from wounded young tissue and co‑culturing with muscle satellite cells increases Pax7⁺ proliferation by ~40% compared with conditioned medium from p21⁺/SASP‑high/mtROS^high cells.
3. Selective senolytic: A CAR‑T construct targeting the surface marker upregulated only on mtROS^high senescent cells (e.g., LC3B‑II‑associated lysosomal antigen) clears the pathogenic subset in aged mice while sparing p21⁺/PDGF‑AA⁺/mtROS^low cells. This treatment should improve grip strength and reduce fibrosis without delaying wound closure relative to untreated aged controls.
4. NAD⁺ rescue: Nicotinamide riboside supplementation in aged mice raises NAD⁺ in senescent cells, lowers mtROS, shifts the persistent phenotype toward the transient PDGF‑AA⁺ profile, and enhances regeneration even without senolytic administration.

Potential Pitfalls

Off‑target effects of the CAR‑T approach could affect activated macrophages that share lysosomal markers; including a suicide switch mitigates this risk. Additionally, the plasticity between transient and persistent states may be context‑dependent; longitudinal single‑cell RNA‑seq time courses are required to confirm phenotype stability.

If the predictions hold, the hypothesis reframes senolytics not as a blunt instrument but as a precision tool that preserves the regenerative chaperone function of senescent cells while removing their deleterious counterparts.